Non-invasive brain stimulation for fatigue in post-acute sequelae of SARS-CoV-2 (PASC)
Brain Stimulation, ISSN: 1935-861X, Vol: 16, Issue: 1, Page: 100-107
2023
- 30Citations
- 3Usage
- 132Captures
- 4Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations30
- Citation Indexes27
- 27
- CrossRef16
- Policy Citations3
- Policy Citation3
- Usage3
- Downloads3
- Captures132
- Readers132
- 132
- Mentions4
- News Mentions4
- News4
Most Recent News
Beyond the Virus: Long COVID’s Neurological Toll
This story was originally published by our sister publication, ContagionLive. Since the start of the COVID-19 pandemic, the persistence or appearance of neurologic symptoms following the
Article Description
and purpose: Fatigue is among the most common persistent symptoms following post-acute sequelae of Sars-COV-2 infection (PASC). The current study investigated the potential therapeutic effects of High-Definition transcranial Direct Current Stimulation (HD-tDCS) associated with rehabilitation program for the management of PASC-related fatigue. Seventy patients with PASC-related fatigue were randomized to receive 3 mA or sham HD-tDCS targeting the left primary motor cortex (M1) for 30 min paired with a rehabilitation program. Each patient underwent 10 sessions (2 sessions/week) over five weeks. Fatigue was measured as the primary outcome before and after the intervention using the Modified Fatigue Impact Scale (MFIS). Pain level, anxiety severity and quality of life were secondary outcomes assessed, respectively, through the McGill Questionnaire, Hamilton Anxiety Rating Scale (HAM-A) and WHOQOL. Active HD-tDCS resulted in significantly greater reduction in fatigue compared to sham HD-tDCS (mean group MFIS reduction of 22.11 points vs 10.34 points). Distinct effects of HD-tDCS were observed in fatigue domains with greater effect on cognitive (mean group difference 8.29 points; effect size 1.1; 95% CI 3.56–13.01; P < .0001) and psychosocial domains (mean group difference 2.37 points; effect size 1.2; 95% CI 1.34–3.40; P < .0001), with no significant difference between the groups in the physical subscale (mean group difference 0.71 points; effect size 0.1; 95% CI 4.47–5.90; P = .09). Compared to sham, the active HD-tDCS group also had a significant reduction in anxiety (mean group difference 4.88; effect size 0.9; 95% CI 1.93–7.84; P < .0001) and improvement in quality of life (mean group difference 14.80; effect size 0.7; 95% CI 7.87–21.73; P < .0001). There was no significant difference in pain (mean group difference −0.74; no effect size; 95% CI 3.66–5.14; P = .09). An intervention with M1 targeted HD-tDCS paired with a rehabilitation program was effective in reducing fatigue and anxiety, while improving quality of life in people with PASC.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1935861X23016741; http://dx.doi.org/10.1016/j.brs.2023.01.1672; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85147225801&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36693536; https://linkinghub.elsevier.com/retrieve/pii/S1935861X23016741; https://digitalcommons.library.tmc.edu/uthgsbs_docs/2192; https://digitalcommons.library.tmc.edu/cgi/viewcontent.cgi?article=3138&context=uthgsbs_docs; https://dx.doi.org/10.1016/j.brs.2023.01.1672
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know